In an interview with <em>Targeted Oncology </em>during the 2018 ASH Annual Meeting, Elizabeth Lihua Budde, MD, PhD, discussed the results seen from this trial for patients with FL and DLBCL. She shared plans for the next steps and how this treatment may impact the patient population.
In an interview with Targeted Oncology, Nathan H. Fowler, MD, discussed the current research for the treatment landscape of relapsed/refractory follicular lymphoma, including 3 clinical trials at MD Anderson that are currently accruing patients with this disease.
In an interview with <em>Targeted Oncology, </em>Stephen Douglas Smith, MD, discussed recent advancements in FL, new treatments currently being evaluated in clinical trials, and the challenges that still exist within this space.
In an interview with <em>Targeted Oncology </em>during the 2019 TCT meeting, Frederick L. Locke, MD, discusses the optimal management of CAR T-cell therapy-related adverse events.
Masatoshi Kudo, MD, PhD, discusses the results from the REFLECT trial and an analysis presented at the 2019 Gastrointestinal Cancers Symposium, as well as other research currently ongoing for this patient population.
In findings from a final PFS analysis of the phase III TOURMALINE-MM3 trial presented during the 2019 Transplantation and Cellular Therapy Meetings, 2-year maintenance therapy with the oral proteasome inhibitor ixazomib following autologous stem cell transplantation improved progression-free survival in patients with multiple myeloma.
Edward B. Garon, MD, discussed these data, as well as other trials investigating immunotherapeutic agents for patients with EGFR-mutant non–small cell lung cancer.
Angela G. Fleischman, MD, PhD, discusses a clinical trial at her institution investigating the JAK1 inhibitor itacitinib in patients with MF. She also highlights other recent advancements for patients with MF, as well as advancements in other MPNs such as ET and PV.
Lead iLLUMINATE study author Carol Moreno, MD, PhD, discusses the safety and efficacy results from the iLLUMINATE trial which led to the FDA approval of ibrutinib plus obinutuzumab in CLL.
A look back at all the FDA news in oncology from the month of January 2019, including several new approvals, breakthrough therapy designations, and a partial clinical hold.
Debu Tripathy, MD, discusses the subgroup analysis from the MONALEESA-7 trial, as well as data from a pooled analysis looking at ribociclib in several clinical trials.
Axel Grothey, MD, discussed the results from a safety lead-in cohort to the BEACON CRC trial and highlighted the significance of these data.
Jochen H. Lorch, MD, discussed some of the ongoing trials at his institution across various types of thyroid cancer.
Ahmed Omar Kaseb, MD, discusses the role of immunotherapy in the treatment landscape of HCC and the impact it could have in the presurgical setting.
Anas Younes, MD, discusses findings from a subset analysis from the PHOENIX trial in patients with DLBCL. He also highlights another trial investigating R-CHOP plus a PD-L1 inhibitor in this patient population.
Srdan Verstovsek, MD, PhD, discusses the current treatment landscape for patients with essential thrombocytopenia and polycythemia vera and shared details of ongoing clinical trials in the field.
John O. Mascarenhas, MD, discusses with <em>Targeted Oncology </em>the recent advancements being made in the treatment of patients with advanced myelofibrosis and highlights some of the unmet needs that still exist within this space.
Jordan Gauthier, MD, MSc, discussed the results presented at the 2018 ASH Annual for this clinical trial and where the research is headed for patients with CLL. He also highlights another promising combination for this patient population that was presented at the meeting as well.
Due to the significant decline in smoking and an increase in advances for early cancer detection and screening, the cancer death rate has declined 27% in the United States from 1991 to 2016, according to the American Cancer Society’s annual report on cancer rates.
Cristina Gasparetto, MD, discusses findings from an ongoing trial of selinexor, daratumumab, and dexamethasone in patients with multiple myeloma
Joseph A. Sparano, MD, explains the current role of liquid biopsies in the breast cancer space and how this role will evolve over time.
A look back at all the FDA news that happened in the month of December 2018, including several new approvals, an accelerated approval, and a priority review.
Nikhil I. Khushalani, MD, discusses the role of adjuvant therapy in patients with melanoma across various subtypes, and also highlights melanoma trials ongoing at Moffitt Cancer Center.<br />
Jeffrey Weber, MD, PhD, discussed the data in support of discontinuing treatment in melanoma and how to properly follow these patients after they go off treatment.<br />
Several oncology experts discuss the FDA approvals they found most significant in 2018.
Kevin Staveley-O’Carroll, MD, PhD, discusses how the field of HCC has advanced over the last few years and how a mouse model at the University of Missouri is being used to further investigate immunotherapy treatment options.<br />
Viola Poeschel, MD, discusses findings from the phase III FLYER trial and how they will impact the treatment landscape for younger patients with favorable-prognosis DLBCL.<br />
Victor A. Chow, MD, discusses findings of a retrospective study that looked at 55 patients with various B-cell lymphomas who progressed after treatment with CD19-specific CAR T cells.
In an interview with <em>Targeted Oncology </em>during the 2018 ASH Annual Meeting<em>, </em>Peter Voorhees, MD, discussed the safety and efficacy findings from the safety run-in cohort and the next steps for the Griffin study.
Although there were a variety of encouraging data presented at the 2018 ASH Annual Meeting, CLL and multiple myeloma undoubtedly ruled the day, according to poll results. As these topics heated up on Twitter, a few experts took a moment to discuss their thoughts on some of the top abstracts that were presented.